Why Semaglutide Lasts a Week But Your Body's Own GLP-1 Lasts Minutes

The GLP-1 hormone your intestine makes naturally has a circulating half-life of roughly one and a half to two minutes. Semaglutide, built from the same hormone, has a half-life of about a week — somewhere near 160 to 168 hours. That difference is the result of two specific, deliberate chemical modifications, not a different drug mechanism.

An enzyme called DPP-4 (dipeptidyl peptidase-4) patrols the bloodstream and clips the first two amino acids off active GLP-1, which inactivates it almost immediately. A second enzyme, neutral endopeptidase, contributes to clearing it further. Any drug built directly from native GLP-1 would need to be injected continuously to have any sustained effect.

Semaglutide has a single amino acid substitution at position 8, exactly where DPP-4 would normally make its cut. That substitution doesn't change what the molecule does at the GLP-1 receptor, but it blocks the enzyme from recognizing and cleaving it there.

The bigger change is a fatty acid chain attached to the molecule at a specific amino acid (lysine 26) through a chemical linker. That fatty tail binds to albumin, the most abundant protein in blood plasma. Bound to albumin, the molecule is too large to be filtered out by the kidneys and is released slowly over time — which is what stretches its effect out to roughly a week instead of minutes.

Liraglutide, an earlier GLP-1 drug, uses a similar fatty-acid-and-albumin strategy but with a shorter fatty acid chain and a different linker, giving it weaker albumin binding and a much shorter effective half-life — which is why it's dosed daily rather than weekly. The length and attachment chemistry of the fatty acid tail is a large part of what determines how often a given GLP-1 drug needs to be injected.